Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smartphone messages may boost medication adherence after liver transplant

NCT ID NCT07728604

Disease control Sponsor: Cansu Yıldız Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial tests whether sending structured digital follow-up messages to liver transplant patients for 12 weeks can help them take their immunosuppressive medication as prescribed and improve their quality of life. Half of the participants receive standard discharge education plus digital messages, while the other half receive standard care alone. Medication adherence and quality of life are measured before and after the intervention using validated questionnaires.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
digital follow-up supported patient education (structured digital messages via smartphone)
What this could lead to
If it works, this could point toward a simple, low-cost way to help liver transplant patients stay on their medication and feel better.
What could go wrong
This is a small, early-stage trial with only 48 participants, so results may not apply to everyone. The benefit of digital messages over standard care may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

48 people

The number who actually took part.

Started

Jan 2026

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older. * Having undergone liver transplantation. * Currently receiving immunosuppressive therapy after liver transplantation. * Ability to read and write in Turkish. * Ability to use a smartphone to receive and follow digital messages. * Willingness to participate voluntarily in the study. * Provision of written informed consent. Exclusion Criteria: * Experiencing an acute rejection episode during the study period. * Presence of cognitive, psychiatric, or communication problems that would interfere with participation in the study. * Inability to regularly follow digital messages. * Difficulty reading and understanding Turkish. * Inability to maintain communication throughout the study period. * Refusal to participate in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver transplantation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Medication Adherence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver transplantation Medication adherence

Contacts and locations

Locations

  • Acibadem İzmir Kent Hospital

    Izmir, 35620, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.